<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21518" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fabry Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Syed Rizwan A.</given-names>
          </name>
          <aff>Tulane Un, Un Med Center New Orleans</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zulfiqar</surname>
            <given-names>Hassam</given-names>
          </name>
          <aff>Hamad Medical Corporation, Doha, Qatar</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hariz</surname>
            <given-names>Anis</given-names>
          </name>
          <aff>Charles Nicolle Hospital, Un. of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Syed Rizwan Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anis Hariz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21518.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Fabry disease is a multi-systemic, X-linked lysosomal storage disease caused by decreased activity of alpha-galactosidase A and results in lysosomal accumulations of neutral glycosphingolipids and globotriaosylceramide GL-3. This activity outlines the evaluation and management of Fabry disease and reviews the interprofessional team's role in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of Fabry disease.</p></list-item><list-item><p>Outline the presentation of a patient with Fabry disease.</p></list-item><list-item><p>Review the management considerations of patients with Fabry disease.</p></list-item><list-item><p>Summarize the importance of collaboration and communication amongst the interprofessional team members to enhance the delivery of care for patients affected by Fabry disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21518&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21518">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21518.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Fabry disease is a multi-systemic, X-linked lysosomal storage disease caused by decreased activity of alpha-galactosidase A and results in lysosomal accumulations of neutral glycosphingolipids and globotriaosylceramide GL-3. Angiokeratoma corporis diffusum is the typical skin lesion seen in Fabry disease and is linked to renal involvement, especially proteinuria. Young adults presenting with a cerebrovascular event in association with myocardial infarction and renal dysfunction should be considered for Fabry disease. Abnormalities in almost any part of the body can be found with more predisposition of the skin, eye, kidney, heart, brain, and peripheral nervous system.<xref ref-type="bibr" rid="article-21518.r1">[1]</xref><xref ref-type="bibr" rid="article-21518.r2">[2]</xref><xref ref-type="bibr" rid="article-21518.r3">[3]</xref></p>
      </sec>
      <sec id="article-21518.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Researchers have identified hundreds of&#x000a0;mutations causing Fabry disease in the gene for alpha-Gal A, located on the X chromosome. Deficiency of alpha-Gal A is the main cause for the lysosomal buildup of glycosphingolipids, principally the cerebroside trihexosides. Progressive glycolipid accumulation with resultant swelling and proliferation of endothelial cells leads to renal failure in the third to the fourth decade, cardiac disease, strokes, and early death. Classic Fabry phenotype is associated with these mutations and presents with multisystem involvement. Milder forms with missense mutations are restricted to cardiac abnormalities.<xref ref-type="bibr" rid="article-21518.r4">[4]</xref><xref ref-type="bibr" rid="article-21518.r5">[5]</xref><xref ref-type="bibr" rid="article-21518.r6">[6]</xref></p>
      </sec>
      <sec id="article-21518.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Prevalence in white male populations has been linked to Fabry disease in a wide range, approximately 1:17,000 to 1:117,000.&#x000a0;Classic Fabry disease mutations are seen in approximately 1:22,000 to 1:40,000 males, and atypical presentations are associated with about 1:1000 to 1:3000 males and 1:6000 to 1:40,000 females.</p>
        <p>Although it is an under-diagnosed condition, the disease is seen in all racial and ethnic groups.</p>
      </sec>
      <sec id="article-21518.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The lysosomal alpha-galactosidase A (alpha-Gal A) deficiency is the main metabolic defect. It is required for the breakdown of the terminal galactose from globotriaosylceramide (Gb3). It leads to the accumulation of Gb3 in various cells and tissues, including skin, eye, kidney, heart, brain, and peripheral nervous system.</p>
        <p>Vascular accumulation secondary to increased endothelial proliferation may manifest as vascular occlusion, ischemia, and infarction. The most common site for vascular dilatation is the vertebrobasilar arteries, followed by smaller cerebral vessels. Young patients presenting with stroke in the setting of Fabry disease have low levels of thrombomodulin (TM) and elevated levels of plasminogen activator inhibitor (PAI) suggestive of the prothrombotic nature of the disease. Postulated mechanisms for stroke in young patients with Fabry disease have&#x000a0;been linked to nitric oxide and non-nitric oxide-dependent endothelial proliferation and dilation and abnormal endothelial nitric oxide synthase (eNOS) activity. Other common sites of Gb3 accumulation include autonomic ganglia, dorsal root ganglia, renal glomerular, tubular, interstitial cells, cardiac muscle cells, vascular smooth muscle cells, valvular fibrocytes, cardiac conduction fibers, and the&#x000a0;cornea.</p>
        <p>Globotriaosylceramide (Gb3) accumulation in the kidney frequently occurs in the glomerulus, followed by deposits in the distal tubule. The preference for Gb3 deposits in these locations is associated with the development of early proteinuria and polyuria. The mechanism of renal sinus cysts formation associated with Fabry disease is not well understood.<xref ref-type="bibr" rid="article-21518.r7">[7]</xref><xref ref-type="bibr" rid="article-21518.r8">[8]</xref><xref ref-type="bibr" rid="article-21518.r9">[9]</xref></p>
      </sec>
      <sec id="article-21518.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Skin biopsy usually&#x000a0;reveals high lipid content. Lipids may also be found inside muscle fibers, endothelial cells,&#x000a0;and ganglion cells.<xref ref-type="bibr" rid="article-21518.r10">[10]</xref></p>
      </sec>
      <sec id="article-21518.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History can reveal high blood pressure in association with renal dysfunction. A thorough medical history should be taken&#x000a0;with specific&#x000a0;attention for heat intolerance with abnormally decreased sweat and tear production, severe heart disease, and cerebrovascular accident (CVA). Attention should be paid to family history, considering the X-linked pattern of genetic inheritance.&#x000a0;Affected males may present with the disease appearing in childhood and early adolescence with the involvement of any organ system. However, it usually presents with painful acroparesthesias, hypohidrosis, gastrointestinal symptoms, namely abdominal cramping and diarrhea. Skin manifestations include microvascular lesions that can appear as small petechiae around the umbilicus, eye manifestations such as lenticular opacities and corneal dystrophy.</p>
        <p>The course of the disease is variable but usually manifests as polyuria, polydipsia, and proteinuria leading to end-stage&#x000a0;renal disease (ESRD), cardiac conduction and valvular defects, CVA, and other neurological manifestations in the third to the fourth decade of&#x000a0;life. Some patients may present with complaints of lymphadenopathy and problems adjusting to heat or cold and strenuous exercise.</p>
      </sec>
      <sec id="article-21518.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Practitioners should&#x000a0;highly suspect Fabry disease should in individuals presenting with the signs and symptoms mentioned above, along with the information gleaned from a thorough personal and family history and physical examination. A basic metabolic profile looking for electrolytes and renal profile, urine sediment for oval fat bodies, ECG, as well as an echocardiogram looking for conduction and structure abnormalities is helpful. Radiological investigations like chest x-ray, CT, CTA, MRI, MRA, and MR spectroscopy can be considered for neurological features. Specific diagnosis is made by documentation of low alpha-Gal A activity in leukocytes or plasma. If enzyme assay or genetic testing is not available, a biopsy of the skin or kidney can help establish the diagnosis. Glycolipid deposits will characterize the biopsy.&#x000a0;Electron microscope&#x000a0;examination of renal biopsy shows concentric layers of inclusions called myeloid or zebra bodies.<xref ref-type="bibr" rid="article-21518.r11">[11]</xref></p>
      </sec>
      <sec id="article-21518.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>This disease cannot be completely cured. Supportive treatment of Fabry disease is to replace the deficient enzyme alpha-galactosidase A (alpha or beta) as soon the diagnosis is made, regardless of the presence or absence of clinical manifestations in affected males and patients on renal replacement therapy. Female carriers and affected males with decreased levels of Alpha-Gal A should get enzyme replacement only in the presence of kidney, heart, or neurological features. Patients on long-term dialysis should also receive enzyme replacement therapy. Hypertension in these patients should be managed with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.<xref ref-type="bibr" rid="article-21518.r12">[12]</xref><xref ref-type="bibr" rid="article-21518.r13">[13]</xref><xref ref-type="bibr" rid="article-21518.r1">[1]</xref></p>
        <p>Either enzyme alpha or beta replacement infusions should be given every two weeks according to body weight calculations. Precautions should be taken considering infusion-related reactions. Slow infusion over one to two hours, along with prior administration of antipyretics, should be considered.</p>
        <p>Fabry disease patients with end-stage renal disease can be safely considered for renal transplantation with the continued enzyme replacement&#x000a0;post-transplant.</p>
      </sec>
      <sec id="article-21518.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Stroke</p>
          </list-item>
          <list-item>
            <p>Cavernous sinus syndromes</p>
          </list-item>
          <list-item>
            <p>Lacunar syndromes</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21518.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Once an individual develops a first stroke, the risk of subsequent strokes is common.</p>
        <p>Heterozygous females tend to have much milder symptoms compared to males.</p>
      </sec>
      <sec id="article-21518.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Angiokeratomas</p>
          </list-item>
          <list-item>
            <p>Cardiomegaly</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>Acroparesthesia</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Vertigo</p>
          </list-item>
          <list-item>
            <p>Altered sweating</p>
          </list-item>
          <list-item>
            <p>Corneal verticillata</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21518.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>A neurologist who specializes in stroke and Fabry disease</p>
        <p>A cardiologist if the stroke is embolic</p>
        <p>A nephrologist for kidney failure</p>
      </sec>
      <sec id="article-21518.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Patients with Fabry disease need to be managed in an&#x000a0;interprofessional team approach, with input and regular follow-up from physicians in neurology and ophthalmology, in addition to experts in managing diseases of kidney, heart, and skin.</p>
        <p>Every year patients should be screened for new-onset symptoms with close monitoring of complete blood count and renal function panel, along with workup for proteinuria. Cardiology monitoring with imaging and electrophysical studies should be done within 1 to 2 years.</p>
        <p>Screening for family members includes an enzymatic assay for deficient alpha-Gal A activity in both symptomatic male and female relatives. There is no supportive evidence for routine prenatal screening and enzyme replacement in infants.</p>
      </sec>
      <sec id="article-21518.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fabry disease is a rare X-linked lysosomal disorder that results in excessive deposition of lipids in the tissues. Young patients usually present with stroke, skin lesions, heart attack, or renal failure. Once the diagnosis is made, an interprofessional approach is vital. The earlier the diagnosis, the better the prognosis. If the disorder is identified during pregnancy, the family will need prenatal counseling.</p>
        <p>The role of the nurse in education is indispensable. The patient and the family need to know about the course of the disease, lifestyle modifications, and the need to follow up.</p>
        <p>Since these patients are prone to strokes, the pharmacist must be fully aware of the types of antiplatelet agents that can be used as prophylaxis. If the stroke is embolic, then warfarin has to be used, and the patient must be told to get regular INR checks. Since the patients are also prone to painful neuropathies, the pharmacist should be familiar with anticonvulsants that are effective&#x000a0;in such disorders. Finally, the pharmacist must be fully aware of the enzyme replacement therapies available. The earlier the enzymes are started, the better the outcomes.&#x000a0;</p>
        <p>Patients with Fabry disease also develop renal and liver failure, and hence the transplant team should be notified to determine if the patient is eligible.</p>
        <p>Finally, the physical and occupational therapist should be consulted to assist with ambulation, use of an ambulatory device, and how to perform daily living activities.<xref ref-type="bibr" rid="article-21518.r6">[6]</xref><xref ref-type="bibr" rid="article-21518.r14">[14]</xref><xref ref-type="bibr" rid="article-21518.r15">[15]</xref>&#x000a0;[Level 3]</p>
        <p>
<bold>Outcome</bold>
</p>
        <p>Fabry disease is heterogeneous in its presentation, but most of its complications are life-threatening. Because the disease is rare, there are no long-term randomized trials, and most of the evidence is short-term&#x000a0;and based on anecdotal case reports and small retrospective case series. End-stage heart and liver disease are often the cause of premature death. Various studies show that the ten-year survival is very low despite enzyme replacement. While kidney transplant has been shown to prolong survival, it is not curative and also subjects the patient to additional morbidity from the side effects of the immunosuppressant drugs. Given this, an interprofessional approach that includes nurses and therapists should try to offer the patient a decent quality of life. <xref ref-type="bibr" rid="article-21518.r16">[16]</xref><xref ref-type="bibr" rid="article-21518.r17">[17]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-21518.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21518&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21518">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/fabry-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21518">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21518/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21518">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21518.s17">
        <title>References</title>
        <ref id="article-21518.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Feldt-Rasmussen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fomin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Germain</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Jovanovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kantola</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Linhart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mignani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Monserrat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Namdar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pieroni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tylki-Szyma&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>T&#x000f8;ndel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viana-Baptista</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weidemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hilz</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>European expert consensus statement on therapeutic goals in Fabry disease.</article-title>
            <source>Mol Genet Metab</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-203</page-range>
            <pub-id pub-id-type="pmid">30017653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>2265</fpage>
            <page-range>2265-2278</page-range>
            <pub-id pub-id-type="pmid">30093456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wasserstein</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Caggana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Desnick</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Edelmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Estrella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Holzman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Kornreich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kupchik</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nafday</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orsini</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants.</article-title>
            <source>Genet Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>631</fpage>
            <page-range>631-640</page-range>
            <pub-id pub-id-type="pmid">30093709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>A Review of Fabry Disease.</article-title>
            <source>Skin Therapy Lett</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>4</fpage>
            <page-range>4-6</page-range>
            <pub-id pub-id-type="pmid">29562089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Pino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernab&#x000e9;u</surname>
                <given-names>A&#x000c1;</given-names>
              </name>
              <name>
                <surname>de Juan-Rivera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Dios Garc&#x000ed;a D&#x000ed;az</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu&#x000f1;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Paniagua</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Posada de la Paz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-P&#x000e9;rez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Santamar&#x000ed;a</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ambros</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Vidau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Torregrosa</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Fabry Nephropathy: An Evidence-Based Narrative Review.</article-title>
            <source>Kidney Blood Press Res</source>
            <year>2018</year>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>406</fpage>
            <page-range>406-421</page-range>
            <pub-id pub-id-type="pmid">29558749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Germain</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Desnick</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Politei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hopkin</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Laney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Linhart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waldek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weidemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Fabry disease revisited: Management and treatment recommendations for adult patients.</article-title>
            <source>Mol Genet Metab</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>416</fpage>
            <page-range>416-427</page-range>
            <pub-id pub-id-type="pmid">29530533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweet</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mestroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MRG</given-names>
              </name>
            </person-group>
            <article-title>Genetic Infiltrative Cardiomyopathies.</article-title>
            <source>Heart Fail Clin</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-224</page-range>
            <pub-id pub-id-type="pmid">29525649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuller</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arends</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langeveld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hollak</surname>
                <given-names>CEM</given-names>
              </name>
            </person-group>
            <article-title>Adaptive pathway development for Fabry disease: a clinical approach.</article-title>
            <source>Drug Discov Today</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>1251</fpage>
            <page-range>1251-1257</page-range>
            <pub-id pub-id-type="pmid">29455022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fabry disease and its cardiac involvement.</article-title>
            <source>J Gen Fam Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>225</fpage>
            <page-range>225-229</page-range>
            <pub-id pub-id-type="pmid">29264031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Lysosomal storage diseases.</article-title>
            <source>Transl Sci Rare Dis</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>2</volume>
            <issue>1-2</issue>
            <fpage>1</fpage>
            <page-range>1-71</page-range>
            <pub-id pub-id-type="pmid">29152458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vijapurapu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alharbi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kozor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bembi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geberhiwot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Steeds</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of the cardiovascular consequences of Fabry disease.</article-title>
            <source>QJM</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>112</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">29878206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madsen</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mogensen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>&#x000c5;K</given-names>
              </name>
              <name>
                <surname>Feldt-Rasmussen</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Enzyme Replacement Therapy During Pregnancy in Fabry Patients : Review of Published Cases of Live Births and a New Case of a Severely Affected Female with Fabry Disease and Pre-eclampsia Complicating Pregnancy.</article-title>
            <source>JIMD Rep</source>
            <year>2019</year>
            <volume>44</volume>
            <fpage>93</fpage>
            <page-range>93-101</page-range>
            <pub-id pub-id-type="pmid">30117110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Onishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fukuzawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Follow-up of Cardiac Fabry Disease Treated by Cardiac Resynchronization Therapy.</article-title>
            <source>CASE (Phila)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>134</fpage>
            <page-range>134-137</page-range>
            <pub-id pub-id-type="pmid">30062265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arends</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wijburg</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vaz</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>van Kuilenburg</surname>
                <given-names>ABP</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Biegstraaten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hollak</surname>
                <given-names>CEM</given-names>
              </name>
              <name>
                <surname>Langeveld</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.</article-title>
            <source>Mol Genet Metab</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-161</page-range>
            <pub-id pub-id-type="pmid">28495078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hennermann</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kurschat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rolfs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Canaan-K&#x000fc;hl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>&#x000dc;&#x000e7;eyler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kampmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karabul</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Giese</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Duning</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stypmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kr&#x000e4;mer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weidemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brand</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <day>29</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <pub-id pub-id-type="pmid">27356758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ers&#x000f6;zl&#x000fc;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desnick</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Huynh-Do</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Canaan-K&#x000fc;hl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barbey</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Genitsch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Cheetham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flammer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schaub</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long-term Outcomes of Kidney Transplantation in Fabry Disease.</article-title>
            <source>Transplantation</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>1924</fpage>
            <page-range>1924-1933</page-range>
            <pub-id pub-id-type="pmid">29688992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21518.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegenthaler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huynh-Do</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Krayenbuehl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Widmer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Debaix</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Olinger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Namdar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.</article-title>
            <source>Int J Cardiol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>15</day>
            <volume>249</volume>
            <fpage>261</fpage>
            <page-range>261-267</page-range>
            <pub-id pub-id-type="pmid">28964554</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
